41. S. Zhai, M. Kemkes, C. E. Kponomaizoun, J. Gerhartz, F. Feller, J. W. Tu, D. E. Pieńkowska, J. Schliehe-Diecks, I. Dressel, M. Gütschow, R. P. Nowak, C. Steinebach, S. Bhatia, F. K. Hansen; Discovery of Histone Deacetylase 8 (HDAC8)-specific Proteolysis-targeting Chimeras with Anti-cancer Activity against Hematological Malignancies; J. Med. Chem.2026, accepted.
2025
40. A. Maksutova, T. M. Geiger, L. Cianni, D. E. Pieńkowska, J. Gerhartz, L. Read, A. Bricelj, A. Herrmann, M. L. Nelles, Y. L. D. Ng, M. D. Hartmann, J. Krönke, I. Sosič, R. P. Nowak, M. Gütschow, C. Steinebach; A Facile Protocol for C(sp2)–C(sp3) Bond Formation Reactions Towards Functionalized E3 Ligase Ligands; ChemMedChem2025, accepted.
39. S. Wittenburg, M. R. Zuleeg, K. Peter, P. Lemnitzer, R. Voget, A. Bricelj, M. Gobec, N. Dierlamm, M. B. Braun, T. M. Geiger, C. Heim, A. Stakemeier, K. G. Wagner, R. P. Nowak, M. D. Hartmann, I. Sosič, M. Gütschow, J. Krönke, C. Steinebach; Enhancing Solubility in VHL-Based PROTACs: Optimized USP7 Degraders for Improved Developability; J. Med. Chem.2025, 68, 15711-15737.
38. A. Bricelj, D. Novak, L. Smrdel, C. Steinebach, I. Sosic, M. Anderluh, M. Gobec; OSMI-4-based PROTACs Do Not Influence O-GlcNAc Transferase and O-GlcNAcylation Levels in Cells. RSC Adv. 2025, 15, 25717.
37. S. Zhai, I. Honin, L. Schäker-Hübner, M. Hanl, L. Jacobi, F. Dressler, D. E. Pieńkowska, P. König, J. Gerhartz, R. Voget, G. Bendas, M. Gütschow, F. Meissner, B. B. Burckhardt, R. P. Nowak, C. Steinebach, F. K. Hansen; Development and Characterization of the First Selective Class IIb Histone Deacetylase Degraders; J. Med. Chem.2025, 68, 13793-13821.
36. N. Strašek Benedik, M. Proj, C. Steinebach, M. Sova, I. Sosič; Targeting TAK1: Evolution of Inhibitors, Challenges, and Future Directions. Pharmacol. Ther.2025, 267, 108810.
35. T. Keuler, D. Ferber, J. Engelhardt, C. Steinebach, N. Kirsch, M. Marleaux, G. Weindl, M. Geyer,* M. Gütschow;* Degrading the Key Component of the Inflammasome: Development of an NLRP3 PROTAC; Chem. Commun.2025, 61, 3001-3004.
34. Perzolli, C. Steinebach, J. Krönke, M. Gütschow, C. M. Zwaan, F. Barneh, O. Heidenreich; PROTAC-mediated GSPT1 Degradation Impairs the Expression of Fusion Genes in Acute Myeloid Leukemia; Cancers 2025, 17, 211.
2024
33. J. Sievers, R. Voget, F. Lu, K. M. Garchitorena, Y. L. D. Ng, C. H. Chau, C. Steinebach, W. D. Figg, J. Krönke, M. Gütschow; Revisiting the Antiangiogenic Mechanisms of Fluorinated Thalidomide Derivatives; Bioorg. Med. Chem. Lett.2024, 110, 129858.
32. B. E. Barton, M. K. Collins, C. H. Chau, H. Choo-Wosoba, D. J. Venzon, C. Steinebach, K. M. Garchitorena, B. Shah, E. L. Sarin, M. Gütschow, W. D. Figg; Preclinical Evaluation of a Novel Series of Polyfluorinated Thalidomide Analogs in Drug Resistant Multiple Myeloma; Biomolecules, 2024, 14, 725.
31. A. Bricelj, Y. L. D. Ng, M. Gobec, R. Kuchta, W. Hu, Š. Javornik, M. Rožič, M. Gütschow, G. Zheng, J. Krönke, C. Steinebach,* I. Sosič;* Design, Synthesis, and Evaluation of BCL-2 Targeting PROTACs; Chem. Eur. J.2024, e202400430.
30. R. Voget, J. Breidenbach, T. Claff, A. Hingst, K. Sylvester, C. Steinebach, L. P. Vu, R. H. Weiße, U. Bartz, N. Sträter, C. E. Müller, M. Gütschow; Development of an Active-site Titrant for SARS-CoV-2 Main Protease as an Indispensable Tool for Evaluating Enzyme Kinetics; Acta Pharm. Sin. B2024, 14, 2349-2357.
2023
29.C. Steinebach,§ A. Bricelj,§ A. Murgai,§ I. Sosič, L. Bischof, Y. L. D. Ng, C. Heim, S. Maiwald, M. Proj, R. Voget, F. Feller, J. Košmrlj, V. Sapozhnikova, A. Schmidt, M. R. Zuleeg, P. Lemnitzer, P. Mertins, F. K. Hansen, M. Gütschow, J. Krönke,* M. D. Hartmann;* Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs; §C.S., A.B. and A.M. contributed equally to this work. J. Med. Chem. 2023, 66, 14513-14543.
28. L. P. Vu, C. J. Diehl,§ R. Casement,§ A. G. Bond,§C. Steinebach, N. Strašek, A. Bricelj, A. Perdih, G. Schnakenburg, I. Sosič, A. Ciulli,* M. Gütschow;* Expanding the Structural Diversity at the Phenylene Core of Ligands for the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Development of Highly Potent Hypoxia-Inducible Factor-1α (HIF-1α) Stabilizers; §C.J.D., R.C. and A.G.B. contributed equally to this work. J. Med. Chem.2023, 66, 12776-12811.
27. Y. L. D. Ng,§ A. Bricelj,§ J. A. Jansen, A. Murgai, K. Peter, K. A. Donovan, M. Gütschow, J. Krönke, C. Steinebach,* I. Sosič;* Heterobifunctional Ligase Recruiters Enable Pan-Degradation of Inhibitor of Apoptosis Proteins; §Y.L.D.N. and A.B. contributed equally to this work. J. Med. Chem.2023, 66, 4703-4733.
26. R. Kuchta, C. Heim, A. Herrmann, S. Maiwald, Y. L. D. Ng, I. Sosič, T. Keuler, J. Krönke, M. Gütschow, M. D. Hartmann,* C. Steinebach;* Accessing Three-Branched High-Affinity Cereblon Ligands for Molecular Glue and Protein Degrader Design; RSC Chem. Biol. 2023, 4, 229-234.
25. F. Pöstges, K. Kayser, J. Appelhaus, M. Monschke, M. Gütschow, C. Steinebach,* K. G. Wagner;* Solubility Enhanced Formulation Approaches to Overcome Oral Delivery Obstacles of PROTACs; Pharmaceutics2023, 15, 156.
2022
24. I. Sosič, A. Bricelj, C. Steinebach,*E3 Ligase Ligand Chemistries: from Building Blocks to Protein Degraders. Chem. Soc. Rev.2022, 51, 3487.
23. T. Keuler,§ B. König,§ N. Bückreiß,§ F. B. Kraft, P. König, L. Schäker-Hübner, C. Steinebach, G. Bendas,* M. Gütschow,* F. K. Hansen;* Development of the First Non-hydroxamate Selective HDAC6 Degraders; §T.K., B.K. and N.B. contributed equally to this work. Chem. Commun.2022, 58, 11087-11090.
22. Murgai, I. Sosič, M. Gobec, P. Lemnitzer, M. Proj, S. Wittenburg, R. Voget, M. Gütschow, J. Krönke,* C. Steinebach;* Expanding the PROTAC Toolbox: Targeted Degradation of the Deubiquitinase USP7 in Cancer; Chem. Commun. 2022, 58, 8858-8861.
21. D. S. J. Miller, S. A. Voell, I. Sosič, M. Proj, O. W. Rossanese, G. Schnakenburg, M. Gütschow, I. Collins, C. Steinebach; Encoding BRAF Inhibitor Functions in Protein Degraders; RSC Med. Chem. 2022, 13, 731-736.
20. Y. L. D. Ng, E. Ramberger, S. Bohl, A. Dolnik, C. Steinebach, T. Conrad, S. Müller, O. Popp, M. Kull, M. Haji, M. Gütschow, H. Döhner, W. Walther, U. Keller, L. Bullinger, P. Mertins, J. Krönke; Proteomic Profiling Reveals CDK6 Upregulation as a Targetable Resistance Mechanism for Lenalidomide in Multiple Myeloma; Nat. Commun.2022, 13, 1009.
19. L. M. Gockel, V. Pfeifer, F. Baltes, R. D. Bachmaier, K. G. Wagner, G. Bendas, M. Gütschow, I. Sosič, C. Steinebach; Design, Synthesis and Characterisation of PROTACs Targeting Androgen Receptor in Prostate and Lung Cancer Models; Arch. Pharm.2022, 355, e202100467.
18. B. Schulte, M. König, B. I. Escher, S. Wittenburg, M. Proj, V. Wolf, C. Lemke, G. Schnakenburg, I. Sosič, H. Streeck, C. E. Müller, M. Gütschow, C. Steinebach; Andrographolide Derivatives Target the KEAP1/NRF2 Axis and Possess Potent anti-SARS-CoV-2 Activity; ChemMedChem2022, 17, e202100732.
2021
17. A. Bricelj,§ Y. L. D. Ng,§ D. Ferber, R. Kuchta, S. Müller, M. Monschke, K. G. Wagner, J. Krönke, I. Sosič, M. Gütschow, C. Steinebach; Influence of Linker Attachment Points on Stability and Neosubstrate Degradation of Cereblon Ligands; §A.B. and Y.L.D.N. contributed equally to this work. ACS Med. Chem. Lett.2021, 12, 1733-1738.
16. I. Sosič,* M. Gobec, C. Steinebach, M. Schlesinger, G. Bendas, M. Gütschow;* Another Structural Correction for 1-Oxo-1H-phenalene-2,3-dicarbonitriles: Synthesis of a Potent BCL-2 Inhibiting 7-Phenoxy Derivative; Arch. Pharm. 2021, 354, e2100151.
15. A. Bricelj, C. Steinebach, R. Kuchta, M. Gütschow,* I. Sosič;* E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points; Front. Chem.2021, 9, 707317.
14. W. Tonnus, C. Meyer, C. Steinebach, A. Belavgeni, A. von Mässenhausen, N. Zamora Gonzalez, F. Maremonti, F. Gembardt, N. Himmerkus, M. Latk, S. Locke, J. Marschner, W. Li, S. Short, S. Doll, I. Ingold, B. Proneth, C. Daniel, N. Kabgani, R. Kramann, S. Motika, P. Hergenrother, S. R. Bornstein, C. Hugo, J. U. Becker, K. Amann, H. J. Anders, D. Kreisel, D. Pratt, M. Gütschow, M. Conrad, A. Linkermann; Dysfunction of the Key Ferroptosis-surveilling Systems Hypersensitizes Mice to Massive Tubular Necrosis During Acute Kidney Injury; Nat. Commun. 2021, 12, 4402
13. C. Heim, S. Maiwald, C. Steinebach, M. K. Collins, J. Strope, C. H. Chau, W. D. Figg, M. Gütschow, M. D. Hartmann; On the Correlation of Cereblon Binding, Fluorination and Antiangiogenic Properties of Immunomodulatory Drugs; Biochem. Biophys. Res. Commun.2021, 534, 67-72.
2016 - 2020
12. M. L. Peach, S. L. Beedie, C. H. Chau, M. K. Collins, S. Markolovic, W. Luo, D. Tweedie, C. Steinebach, N. H. Greig, M. Gütschow, N. Vargesson, M. C. Nicklaus, W. D. Figg; In Silico Cereblon Binding Analysis of Novel Thalidomide Analogs; Molecules2020, 25, 5683.
11. K. Krome, T. G. Becker, S. Kehraus, A. Schiefer, C. Steinebach, T. Aden, S. J. Frohberger, Á. López Mármol, D. Kapote, R. Jansen, L. Chaverra-Muñoz, M. P. Hübner, K. Pfarr, T. Hesterkamp, M. Stadler, M. Gütschow, G. M. König, A. Hoerauf, K. G. Wagner; Solubility and Stability Enhanced Oral Formulations for the Anti-Infective Corallopyronin A; Pharmaceutics2020, 12, E1105.
10. S. Kuwahara-Ota, Y. Shimura, C. Steinebach, R. Isa, J. Yamaguchi, D. Nishiyama, Y. Fujibayashi, T. Takimoto-Shimomura, Y. Mizuno, Y. Matsumura-Kimoto, T. Tsukamoto, Y. Chinen, T. Kobayashi, S. Horiike, M. Taniwaki, M. Gütschow, J. Kuroda; Lenalidomide and Pomalidomide Potently Interfere with Induction of Myeloid-derived Suppressor Cells in Multiple Myeloma; Br. J. Haematol.2020, 191, 784-795.
9. C. Steinebach, S. A. Voell, L. P. Vu, A. Bricelj, I. Sosič, G. Schnakenburg, M. Gütschow; A Facile Synthesis of Ligands for the von Hippel-Lindau E3 Ligase; Synthesis2020, 52, 2521-2527.
8. C. Steinebach,§ Y. L. D. Ng,§ I. Sosič, C.-S. Lee, S. Chen, S. Lindner, L. P. Vu, A. Bricelj, R. Haschemi, M. Monschke, E. Steinwarz, K. G. Wagner, G. Bendas, J. Luo, M. Gütschow,* J. Krönke;* Systematic Exploration of Different E3 Ubiquitin Ligases: An Approach Towards Potent and Selective CDK6 Degraders; §C.S. and Y.L.D.N. contributed equally to this work. Chem. Sci.2020, 11, 3474-3486.
7. C. Steinebach, I. Sosič, S. Lindner, A. Bricelj, F. Kohl, Y. L. D. Ng, M. Monschke, K. G. Wagner, J. Krönke, M. Gütschow; A MedChem Toolbox for Cereblon-directed PROTACs; Med. Chem. Comm.2019, 10, 1034-1041.
6. S. Lindner,§C. Steinebach,§ H. Kehm, M. Mangold, M. Gütschow, J. Krönke; Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs; §S.L. and C.S. contributed equally to this work. J. Vis. Exp.2019, 147, e59472.
5. C. Steinebach,§ H. Kehm,§ S. Lindner, L. P. Vu, S. Köpff, Á. López Mármol, C. Weiler, K. G. Wagner, M. Reichenzeller, J. Krönke,* M. Gütschow;* PROTAC-mediated Crosstalk Between E3 Ligases; §C.S. and H.K. contributed equally to this work. Chem. Commun.2019, 55, 1821-1824.
4. C. Steinebach,§ S. Lindner,§ N. D. Udeshi, D. C. Mani, H. Kehm, S. Köpff, S. A. Carr, M. Gütschow,* J. Krönke;* Homo-PROTACs for the Chemical Knockdown of Cereblon; §C.S. and S.L. contributed equally to this work. ACS Chem. Biol.2018, 13, 2771-2782.
3. C. Steinebach, A. Ambrożak, S. Dosa, S. L. Beedie, J. D. Strope, G. Schnakenburg, W. D. Figg, M. Gütschow; Synthesis, Structural Characterization and Antiangiogenic Activity of Polyfluorinated Benzamides; ChemMedChem2018, 13, 2010-2089.
2. A. Ambrozak, C. Steinebach, E. R. Gardner, S. L. Beedie, G. Schnakenburg, W. D. Figg, M. Gütschow; Synthesis and Antiangiogenic Properties of Tetrafluorophthalimido and Tetrafluorobenzamido Barbituric Acids; ChemMedChem2016, 11, 2621-2629.
1.C. Steinebach, A. C. Schulz-Fincke, G. Schnakenburg, M. Gütschow; In Situ Generation and Trapping of Thioimidates: An Intermolecular Tandem Reaction to 4-Acylimino-4H-3,1-benzothiazines; RSC Adv.2016, 6, 15430-15440.
